Development of a multi-pathogen chimeritope vaccine for tick borne diseases

开发用于蜱传疾病的多病原体嵌合体疫苗

基本信息

  • 批准号:
    9526584
  • 负责人:
  • 金额:
    $ 51.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2019-07-31
  • 项目状态:
    已结题

项目摘要

Lyme disease (LD) and human granulocytic anaplasmosis (HGA), are significant public health threats. LD is caused by Borrelia burgdorferi, B. garinii, B. bavariensis, and B. afzelii. HGA is caused by Anaplasma phagocytophilum (Ap). The CDC estimates there are between 300-600,000 LD cases per year in the US with similar numbers in Europe. The number of cases of HGA is less clear but since being designated as a reportable disease in 2009, case numbers are steadily increasing. In 2010, active surveillance in endemic areas revealed an incidence rate of HGA of >50 cases per 100,000 population (a number considered to be a significant underestimate). Preventive strategies for tick borne diseases are ineffective. With the expansion of the endemic regions for LD and HGA, better recognition of their true incidence, the severity of these diseases, and the potential complications associated with co-infection, a vaccine that protects against multiple tick borne pathogens is needed. In this study we will develop a novel chimeric linear epitope based vaccine (chimeritope) for LD and HGA. Proof of principle for chimeritope vaccines has been demonstrated by the successful development of a highly efficacious canine LD vaccine. The same novel conceptual approach that was applied in developing the canine vaccine will be employed to construct a human vaccine for both LD and HGA. The chimeric vaccinogen will consist of defined linear epitopes of the OspA, B and C proteins of the Lyme disease spirochetes and defined domains of Ap proteins OmpA, Asp14 and AipA. The polyvalent nature of the construct will provide protection against diverse strains of the multiple species of Borrelia that cause LD and the causative agent of HGA. The resulting vaccine will offer a new preventive strategy for these significant public health threats. The proposed work is timely, highly significant and addresses an NIH priority area. This study will have broad overall impact as the knowledge gained can be applied in the design of other epitope based multi-valent, multi-disease vaccines.
莱姆病(LD)和人类粒细胞无形体病(HGA)是严重威胁公共卫生的疾病。LD是 由伯氏疏螺旋体、加里尼疏螺旋体、巴伐利亚疏螺旋体和费氏疏螺旋体引起。HGA是由无浆体引起的 吞噬细胞数(AP)。疾控中心估计,美国每年有300-60万例LD病例 在欧洲也有类似的数字。HGA病例的数量不太清楚,但由于被指定为 2009年出现可报告疾病,病例数量稳步增加。2010年,积极监测地方病流行 地区显示HGA的发病率为每10万人50例(这个数字被认为是 严重低估)。壁虱传播疾病的预防策略是无效的。随着规模的扩大 关于LD和HGA的流行地区,更好地认识它们的真实发病率、这些疾病的严重程度 疾病以及与混合感染相关的潜在并发症,一种预防多发性肺炎的疫苗 壁虱传播的病原体是必需的。在这项研究中,我们将开发一种基于嵌合线性表位的新型疫苗 (嵌合体)用于LD和HGA。嵌合体疫苗的原理证明是由 成功研制出一种高效犬乳突病疫苗。同样新颖的概念方法, 将被用于开发犬类疫苗,并将用于构建针对LD和 HGA。嵌合疫苗原将由确定的OspA、B和C蛋白的线性表位组成 莱姆病螺旋体和AP蛋白OmpA、Asp14和AipA的结构域。多价性 将对引起LD的多种疏螺旋体的不同菌株提供保护 和HGA的致病因子。由此产生的疫苗将为这些重大疾病提供一种新的预防策略 公共卫生威胁。拟议的工作是及时的、非常重要的,并涉及国家卫生研究院的一个优先领域。这 研究将产生广泛的整体影响,因为所获得的知识可以应用于其他表位的设计 以多价、多病疫苗为基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD T MARCONI其他文献

RICHARD T MARCONI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD T MARCONI', 18)}}的其他基金

OspC and its role in defining host range and dissemination properties
OspC 及其在定义主机范围和传播属性中的作用
  • 批准号:
    10345736
  • 财政年份:
    2022
  • 资助金额:
    $ 51.05万
  • 项目类别:
OspC and its role in defining host range and dissemination properties
OspC 及其在定义主机范围和传播属性中的作用
  • 批准号:
    10674690
  • 财政年份:
    2022
  • 资助金额:
    $ 51.05万
  • 项目类别:
Chimeric epitope based vaccines for tick borne infections
用于蜱传感染的嵌合表位疫苗
  • 批准号:
    9982205
  • 财政年份:
    2019
  • 资助金额:
    $ 51.05万
  • 项目类别:
Chimeric epitope based vaccines for tick borne infections
用于蜱传感染的嵌合表位疫苗
  • 批准号:
    10219068
  • 财政年份:
    2019
  • 资助金额:
    $ 51.05万
  • 项目类别:
Chimeric epitope based vaccines for tick borne infections
用于蜱传感染的嵌合表位疫苗
  • 批准号:
    10438610
  • 财政年份:
    2019
  • 资助金额:
    $ 51.05万
  • 项目类别:
The role of OspC in Borrelia pathogenesis
OspC 在疏螺旋体发病机制中的作用
  • 批准号:
    7826206
  • 财政年份:
    2009
  • 资助金额:
    $ 51.05万
  • 项目类别:
The role of OspC in Borrelia pathogenesis
OspC 在疏螺旋体发病机制中的作用
  • 批准号:
    7650493
  • 财政年份:
    2008
  • 资助金额:
    $ 51.05万
  • 项目类别:
Treponema denticola, complement regulatory proteins and periodontal disease
齿垢密螺旋体、补体调节蛋白和牙周病
  • 批准号:
    7208842
  • 财政年份:
    2007
  • 资助金额:
    $ 51.05万
  • 项目类别:
Treponema denticola, complement regulatory proteins and periodontal disease
齿垢密螺旋体、补体调节蛋白和牙周病
  • 批准号:
    8061662
  • 财政年份:
    2007
  • 资助金额:
    $ 51.05万
  • 项目类别:
Treponema denticola, complement regulatory proteins and periodontal disease
齿垢密螺旋体、补体调节蛋白和牙周病
  • 批准号:
    7807090
  • 财政年份:
    2007
  • 资助金额:
    $ 51.05万
  • 项目类别:

相似海外基金

Tick Immune Signaling, Microbiota, and Acquisition of Borrelia burgdorferi and Anaplasma phagocytophilum
蜱免疫信号传导、微生物群以及伯氏疏螺旋体和嗜吞噬细胞无形体的获得
  • 批准号:
    10222514
  • 财政年份:
    2018
  • 资助金额:
    $ 51.05万
  • 项目类别:
Tick Immune Signaling, Microbiota, and Acquisition of Borrelia burgdorferi and Anaplasma phagocytophilum
蜱免疫信号传导、微生物群以及伯氏疏螺旋体和嗜吞噬细胞无形体的获得
  • 批准号:
    9976322
  • 财政年份:
    2018
  • 资助金额:
    $ 51.05万
  • 项目类别:
Tick Immune Signaling, Microbiota, and Acquisition of Borrelia burgdorferi and Anaplasma phagocytophilum
蜱免疫信号传导、微生物群以及伯氏疏螺旋体和嗜吞噬细胞无形体的获得
  • 批准号:
    10440404
  • 财政年份:
    2018
  • 资助金额:
    $ 51.05万
  • 项目类别:
Anaplasma phagocytophilum modulate tick gene expression for its survival and transmission from the vector host
嗜吞噬细胞无形体调节蜱基因表达以使其存活并从载体宿主传播
  • 批准号:
    10322351
  • 财政年份:
    2017
  • 资助金额:
    $ 51.05万
  • 项目类别:
Anaplasma phagocytophilum modulate tick gene expression for its survival and transmission from the vector host
嗜吞噬细胞无形体调节蜱基因表达以使其存活并从载体宿主传播
  • 批准号:
    10203774
  • 财政年份:
    2017
  • 资助金额:
    $ 51.05万
  • 项目类别:
Anaplasma phagocytophilum modulate tick gene expression for its survival and transmission from the vector host
嗜吞噬细胞无形体调节蜱基因表达以使其存活并从载体宿主传播
  • 批准号:
    9398343
  • 财政年份:
    2017
  • 资助金额:
    $ 51.05万
  • 项目类别:
Dynamics of Anaplasma phagocytophilum infection through tick development
蜱发育过程中嗜吞噬细胞无形体感染的动态
  • 批准号:
    8868727
  • 财政年份:
    2015
  • 资助金额:
    $ 51.05万
  • 项目类别:
Anaplasma phagocytophilum hijacking of host cell monoubiquitination
嗜吞噬细胞无形体劫持宿主细胞单泛素化
  • 批准号:
    8784189
  • 财政年份:
    2013
  • 资助金额:
    $ 51.05万
  • 项目类别:
Anaplasma phagocytophilum hijacking of host cell monoubiquitination
嗜吞噬细胞无形体劫持宿主细胞单泛素化
  • 批准号:
    8637532
  • 财政年份:
    2013
  • 资助金额:
    $ 51.05万
  • 项目类别:
The roles of Anaplasma phagocytophilum surface proteins in cellular invasion
嗜吞噬细胞无形体表面蛋白在细胞侵袭中的作用
  • 批准号:
    8510769
  • 财政年份:
    2012
  • 资助金额:
    $ 51.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了